<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041452</url>
  </required_header>
  <id_info>
    <org_study_id>282/18</org_study_id>
    <nct_id>NCT05041452</nct_id>
  </id_info>
  <brief_title>Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension</brief_title>
  <official_title>Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to use multiparametric MRI to investigate any differences in&#xD;
      myocardial structure and function in patients with noncirrhotic portal hypertension compared&#xD;
      with a control group with liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The term &quot;cirrhotic cardiomyopathy&quot; (CCM) was defined in 2005 according to expert consensus&#xD;
      at the &quot;World Congress of Gastroenterology&quot; in Montreal as a clinical phenotype in patients&#xD;
      with liver cirrhosis consisting of systolic and diastolic dysfunction and a complementary&#xD;
      criterion, such as electrophysiological changes, without the presence of a known underlying&#xD;
      cardiac disease. For a long time, CCM was considered to result from toxic effects of alcohol&#xD;
      consumption. The current view is that CCM is a separate entity independent of the various&#xD;
      etiologies of liver cirrhosis. Thus, generally impaired liver function and portal&#xD;
      hypertension with splanchnic vasodilation leads to altered hemodynamic conditions with&#xD;
      central hypovolemia, increased activation of volume and baroreceptors, especially of the&#xD;
      sympathetic nervous system, resulting in a &quot;hyperdynamic syndrome&quot; with increased cardiac&#xD;
      stress. However, the contribution of portal hypertension to CCM is unclear.&#xD;
&#xD;
      With new MRI techniques such as cardiac T1 and T2 mapping and extracellular volume fraction&#xD;
      (ECV), quantitative parameters are available to detect pathologies of the myocardium before&#xD;
      they become detectable with conventional techniques in cardiac MRI or echocardiography.&#xD;
&#xD;
      The aim of this study is to use multiparametric MRI to investigate any differences in&#xD;
      myocardial structure and function in patients with noncirrhotic portal hypertension compared&#xD;
      with a control group with liver cirrhosis and to investigate a quantifiable correlation&#xD;
      between cardiac, hepatic, and splenic parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial T1 relaxation time</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>T1 relaxation times will be obtained to asses acute myocardial injury and fibrosis. T1 maps will be analyzed using a segmental approach by region of interest analysis. T1 relaxation times are given in [ms].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial T2 relaxation time</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>T2 relaxation times will be obtained to asses myocardial edema. T2 maps will be analyzed using a segmental approach by region of interest analysis. T2 relaxation times are given in [ms].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial ECV</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>Myocardial extracellular volume will be obtained to asses extracellular space/myocardial fibrosis. ECV values will be calculated using a segmental approach by region of interest analysis of native and contrast-enhanced T1 relaxation maps. ECV values are given in [%].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial strain</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>Cardiac magnetic resonance feature-tracking will be used to asses left ventricular longitudinal, circumferential and radial strain.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension, Portal</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Noncirrhotic portal hypertension (NCPH)</arm_group_label>
    <description>Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhotic portal hypertension</arm_group_label>
    <description>Patients with cirrhosis and portal hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance scan</intervention_name>
    <description>Multiparametric cardiac magnetic resonance, including functional and structural parameters</description>
    <arm_group_label>Cirrhotic portal hypertension</arm_group_label>
    <arm_group_label>Noncirrhotic portal hypertension (NCPH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with clinically diagnosed noncirrhotic portal hypertension who are being treated&#xD;
        at the Medical Clinic and Polyclinic I of the University Hospital Bonn are included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. noncirrhotic portal hypertension&#xD;
&#xD;
          2. age at least 18 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. underlying cardiac disease, e.g., coronary heart disease/myocardial infarction,&#xD;
             myocarditis, cardiomyopathies of other causes, congenital heart disease&#xD;
&#xD;
          2. patients who are using a intrauterinpessare for contraception&#xD;
&#xD;
          3. pregnant and breastfeeding women&#xD;
&#xD;
          4. patients with contraindications for MRI (not suitebale metallic implants)&#xD;
&#xD;
          5. patients with contraindications for MRI contrast agents (renal insufficiency, allergy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Julian A Luetkens, PD Dr. med.</last_name>
    <phone>+49 228 287-15960</phone>
    <email>julian.luetkens@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Isaak, Dr. med.</last_name>
    <phone>+49 228 287-15960</phone>
    <email>alexander.isaak@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn, Clinic for Diagnostic and Interventional Radiology</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian A Luetkens, PD Dr.</last_name>
      <email>julian.luetkens@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Isaak, Dr.</last_name>
      <email>alexander.isaak@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Julian A Luetkens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Medical Clinic and Polyclinic I</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Praktiknjo, Dr. med.</last_name>
      <phone>+49 228 287-15770</phone>
      <email>michael.praktiknjo@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Jansen, Dr. med.</last_name>
      <phone>+49 228 287-15770</phone>
      <email>christian.jansen@ukbonn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Julian Alexander Luetkens</investigator_full_name>
    <investigator_title>Principal Investigator, Senior Physician</investigator_title>
  </responsible_party>
  <keyword>Cardiac MRI</keyword>
  <keyword>Hepatic MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

